Lancet (London, England) Snape, M D 2022, ' Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2) : a single-blind, randomised, phase 2, non-inferiority trial ', Lancet, vol. 399, no. 10319, pp. 36-49 . https://doi.org/10.1016/S0140-6736(21)02718-5
Jowett, S, Kodabuckus, S, Ford, G A, Hobbs, F D R, Payne, R A & Sheppard, J P 2022, ' Cost-effectiveness of antihypertensive deprescribing in primary care : a Markov modelling study using data from the OPTiMISE trial ', Hypertension, vol. 79, no. 5, pp. 1122-1131 . https://doi.org/10.1161/HYPERTENSIONAHA.121.18726